A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

DOI: 10.1111/jsm.12357
Journal of Sexual Medicine, 2014, 11, 187-96.

#	Paper	IF	Citations
54	Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. *International Journal of General Medicine*, **2014**, 7, 271-6	2.3	3
53	Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model. *Journal of Sexual Medicine*, **2014**, 11, 1159-72	1.1	19
52	The use of pharmacotherapy for male patients with urgency and stress incontinence. *Current Opinion in Urology*, **2014**, 24, 571-7	2.8	7
51	Nonresponse to PDE5 inhibitors in erectile dysfunction. Part 2. *Human Andrology*, **2014**, 4, 45-53	1	
50	Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. *Expert Opinion on Drug Safety*, **2014**, 13, 1187-97	4.1	28
49	The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. *Journal of Sexual Medicine*, **2014**, 11, 1539-45	1.1	34
48	The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. *Current Urology Reports*, **2015**, 16, 80	2.9	0
47	Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. *Therapeutics and Clinical Risk Management*, **2015**, 11, 507-13	2.9	8
46	Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. *Therapeutic Advances in Urology*, **2015**, 7, 249-64	3.2	17
45	Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations. *Patient Preference and Adherence*, **2016**, 10, 1205-15	2.4	4
44	Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. *Central European Journal of Urology*, **2016**, 69, 398-403	0.9	5
43	Combination therapy for the treatment of lower urinary tract symptoms in men. *Revista Mexicana De Urologia*, **2016**, 76, 360-369	1	
42	[Bullous fixed drug eruption of the glands due to tadalafil: A case report]. *Progres En Urologie*, **2016**, 26, 435-6	0.9	1
41	New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. *BMC Urology*, **2016**, 16, 58	2.2	13
40	Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *European Urology*, **2016**, 70, 124-133	10.2	85
39	Words of Wisdom: Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction. *European Urology*, **2016**, 69, 174	10.2	2
38	Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. *European Urology*, **2017**, 71, 570-581	10.2	36

37	Effects of combined treatment of tadalafil and tamsulosin on bladder dysfunction via the inhibition of afferent nerve activities in a rat model of bladder outlet obstruction. *International Urology and Nephrology*, **2018**, 50, 839-844	2.3	3
36	Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. *Aging Male*, **2018**, 21, 272-280	2.1	9
35	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. *The Cochrane Library*, **2018**, 11, CD010060	5.2	8
34	[Influence of medical BPS treatment on sexual function]. *Der Urologe*, **2018**, 57, 1464-1471		3
33	Low dose rate prostate brachytherapy. *Translational Andrology and Urology*, **2018**, 7, 341-356	2.3	21
32	Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. **2018**, 51-88		
31	Medical Aspects of the Treatment of LUTS/BPH: Combination Therapies. **2018**, 217-239		
30	Efficacy and safety of PDE5-Is and □1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs. *BMC Urology*, **2018**, 18, 30	2.2	5
29	Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction. *American Journal of Men's Health*, **2019**, 13, 1557988319882597	2.2	8
28	Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men. *Current Geriatrics Reports*, **2019**, 8, 310-314	1.3	0
27	Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients. *Journal of Clinical Urology*, **2019**, 12, 223-227	0.2	1
26	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. *European Urology*, **2019**, 75, 129-168	10.2	12
25	Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. *European Urology Focus*, **2020**, 6, 537-558	5.1	14
24	Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. *BJU International*, **2020**, 125, 718-724	5.6	7
23	Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. *Current Urology Reports*, **2020**, 21, 56	2.9	11
22	Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis. *Medicine (United States)*, **2020**, 99, e22834	1.8	2
21	Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis. *American Journal of Men's Health*, **2020**, 14, 1557988320980180	2.2	2
20	Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. *Frontiers in Pharmacology*, **2020**, 11, 658	5.6	14

19	Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. *International Journal of Clinical Practice*, **2020**, 74, e13530	2.9	3
18	Modern best practice in the management of benign prostatic hyperplasia in the elderly. *Therapeutic Advances in Urology*, **2020**, 12, 1756287220929486	3.2	6
17	The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. *Medicine (United States)*, **2020**, 99, e18802	1.8	12
16	The hemodynamic interactions of combination therapy with Eblockers and phosphodiesterase-5 inhibitors compared to monotherapy with Eblockers: a systematic review and meta-analysis. *International Urology and Nephrology*, **2020**, 52, 1407-1420	2.3	1
15	Novel HPTLC densitometric methods for determination of tamsulosin HCl and tadalafil in their newly formulated dosage form: Comparative study and green profile assessment. *Biomedical Chromatography*, **2020**, 34, e4850	1.7	13
14	Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis. *BioMed Research International*, **2020**, 2020, 1419520	3	3
13	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. *European Urology Focus*, **2021**, 7, 432-439	5.1	2
12	Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis. *American Journal of Men's Health*, **2021**, 15, 1557988321997725	2.2	
11	A COMPARATIVE STUDY OF TADALAFIL & TAMSULOSIN COMBINATION THERAPY VERSUS ALFUZOSIN MONOTHERAPY IN SEXUALLY ACTIVE PATIENTS OF BENIGN PROSTATIC HYPERPLASIA.. **2021**, 22-25		
10	Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical study. *International Journal of Clinical Practice*, **2021**, 75, e14184	2.9	0
9	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on Blockers and 5-Alpha Reductase Inhibitors. *Uro*, **2021**, 1, 82-98		
8	Study of phosphodiesterase 5 inhibitors and adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2020**, 72, 13-21	4.4	9
7	Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. *Asian Journal of Andrology*, **2016**, 18, 723-31	2.8	8
6	A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With Blockers and Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction. *International Neurourology Journal*, **2015**, 19, 237-45	2.6	5
5	Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?. *World Journal of Nephrology*, **2015**, 4, 138-47	3.6	9
4	Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. *Medical Science Monitor*, **2020**, 26, e923179	3.2	1
3	Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. *Minerva Urology and Nephrology*, **2022**, 73,	2.3	0
2	Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-14		0

1	A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia. **2023**, 17, 155798832311550	0